U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
  1. Regulatory Information

GUIDANCE DOCUMENT

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry April 2015

Draft

Not for implementation. Contains non-binding recommendations.

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry

Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research

This guidance provides information on how the FDA will define and process submissions from application holders2 for modifications and revisions3 to approved risk evaluation and mitigation strategies (REMS). Specifically, this guidance provides information on what types of changes to REMS will be considered modifications of the REMS, as described in section 505-1(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and what types of changes will be considered revisions of the REMS.5 There are different procedures for submission of REMS modifications and revisions to the FDA, as well as different time frames for FDA review and action on such changes. This guidance provides information on how REMS modifications and revisions should be submitted to the FDA, and the FDA’s process for reviewing and acting on these submissions. The definitions of REMS modifications and revisions set forth in this 30 guidance apply to all types of REMS. This guidance is issued pursuant to sections 505­ 31 1(h)(2)(A)(ii), (iii), and (iv) of the FD&C Act.


Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.